Postpartum Pre-exposure Prophylaxis (PrEP) Study to Evaluate an Adherence Promotion Package for Postpartum Women on PrEP

NACompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

May 18, 2021

Conditions
HIV-1-infection
Interventions
BEHAVIORAL

HIVST and enhanced adherence biofeedback

"The intervention includes the provision of an OraQuick HIV self-test (HIVST) for the woman and one test for each of her reported sex partners, along with instructions on how to use and interpret the results. Women were asked to report back within one month if their partner was able to test via a SMS, WhatsApp or by bringing in the test to confirm that he had tested.~Women then received adherence based feedback following the urine lateral flow assay (that measures recent tenofovir use in past 48 hours). Study counsellors requested that women provide a urine sample that was tested using the UrSure/Orasure test that provides feedback on the result in 2-3 minutes. Counselors provided counseling based on the results including how to improve daily adherence (for women without tenofovir present in their urine) and importance of condom use."

DIAGNOSTIC_TEST

Orasure/UrSure test

See above

Trial Locations (1)

Unknown

Gugulethu Midwife Obstetric Unit, Cape Town

All Listed Sponsors
collaborator

University of Cape Town

OTHER

lead

University of California, Los Angeles

OTHER

NCT04897737 - Postpartum Pre-exposure Prophylaxis (PrEP) Study to Evaluate an Adherence Promotion Package for Postpartum Women on PrEP | Biotech Hunter | Biotech Hunter